3-[(1-甲基-2-苯基乙基)氨基]丙腈 | 16397-28-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-[(1-甲基-2-苯基乙基)氨基]丙腈
• 英文名称: fenproporex
• 英文别名: N-(1-methyl-2-phenyl-ethyl)-β-alanine nitrile；N-(1-Methyl-2-phenyl-aethyl)-β-alanin-nitril；N-<β-Cyan-ethyl>-β-phenyl-isopropylamin；3-(1-phenylpropan-2-ylamino)propanenitrile
• CAS: 16397-28-7
• 化学式: C₁₂H₁₆N₂
• 分子量: 188.272
• InChiKey: IQUFSXIQAFPIMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  35.8
• 氢给体数：
  1
• 氢受体数：
  2

ADMET

代谢

很大一部分，60-80%，的芬普罗普瑞克斯会迅速转化为安非他命。除了安非他命和未改变的芬普罗普瑞克斯外，从尿样中还鉴定出了14种其他代谢物。据认为存在两条相互作用的代谢途径。主要的代谢途径被认为涉及芳香族羟基化、甲基化和N-脱烷基化侧链降解形成安非他命。次要途径涉及安非他命的β-羟基化形成诺芬尼。

A large portion, 60-80%, of fenproporex is rapidly converted into amphetamine. Besides amphetamine, and unchanged fenproporex, 14 other metabolites were identified from urine samples. Two interacting metabolic pathways are believed to exist. The major pathway is believed to involve ring-degradation by aromatic hydroxylation, methylation, and side chain degradation by N-dealkyation to form amphetamine. The minor pathway involves the beta-hydroxylation of amphetamine to form norephedrine. [6]

来源:DrugBank

吸收、分配和排泄

• 消除途径

经肾脏随尿液排出，主要是作为amphetamine（安非他明），但5-9%以原药形式不变。

Renally eliminated in the urine, mainly as amphetamine, but 5-9% as unchanged drug.

来源:DrugBank

吸收、分配和排泄

• 清除

苯丙胺类代谢物在服用芬普罗普法（一种药物）后可以在几天内被检测到（在一项研究中，最长时间可达119小时）。[2]

The amphetamine metabolite can be detected for several days after the administration of forproporex (up to 119h, in one study). [2]

来源:DrugBank

反应信息

• 作为反应物：
  描述：

  3-[(1-甲基-2-苯基乙基)氨基]丙腈 、 三苯基氯甲烷 在 三乙胺 作用下， 以 苯 为溶剂， 生成 N-Trityl-N-<β-cyan-ethyl>-β-phenyl-isopropylamin
  参考文献：
  名称：

  Butskus,P.F. et al., Journal of Organic Chemistry USSR (English Translation), 1968, vol. 4, p. 2048 - 2049

  摘要：

  DOI：
• 作为产物：
  描述：

  非那明 、 丙烯腈 生成 3-[(1-甲基-2-苯基乙基)氨基]丙腈
  参考文献：
  名称：

  Base Strengths of Cyanoamines¹

  摘要：

  DOI：

  10.1021/ja01555a014

文献信息

• [EN] METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] MÉTHYLOXAZOLES ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016089721A1

  公开（公告）日：2016-06-09

  The present invention is directed to methyl oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及甲基噁唑化合物，其为促进睡眠的受体拮抗剂。本发明还涉及所述化合物在潜在治疗或预防涉及促进睡眠的神经和精神疾病和疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及促进睡眠的疾病中的用途。
• 1,5-Substituted indol-2-yl amide derivatives
  申请人：Nettekoven Matthias

  公开号：US20070123515A1

  公开（公告）日：2007-05-31

  The present invention relates to compounds of formula I wherein R 1 to R 4 and G are as defined in the description and claims and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

  本发明涉及式I的化合物，其中R1至R4和G如描述和索赔中定义的，并且其药学上可接受的盐。这些化合物可用于治疗和/或预防与H3受体调节相关的疾病。
• INDOL-2-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES
  申请人：Nettekoven Matthias

  公开号：US20080188484A1

  公开（公告）日：2008-08-07

  The present invention relates to compounds of formula I wherein A and R 1 to R 4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

  本发明涉及公式I的化合物，其中A和R1至R4如描述和声明中所定义，并且其药学上可接受的盐。这些化合物可用于治疗和/或预防与H3受体调节相关的疾病。
• BENZOFURAN AND BENZOTHIOPHENE-2-CARBOXYLIC ACID AMIDE DERIVATIVES
  申请人：Mohr Peter

  公开号：US20090029976A1

  公开（公告）日：2009-01-29

  The present invention relates to compounds of formula I wherein X, A and R 1 to R 4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

  本发明涉及公式I的化合物，其中X，A和R1至R4如描述和索赔中所定义，并且其药学上可接受的盐。这些化合物可用于治疗和/或预防与H3受体调节相关的疾病。
• [EN] NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS<br/>[FR] NOUVEAUX AGENTS ANTIDIABÉTIQUES UTILES AVEC DES DÉRIVÉS DE BENZIMIDAZOLE CYCLIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2010051176A1

  公开（公告）日：2010-05-06

  Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

  结构式（I）的新化合物是AMP-蛋白激酶的激活剂，可用于治疗、预防和抑制由AMPK激活的蛋白激酶介导的疾病。本发明的化合物对于治疗2型糖尿病、高血糖、代谢综合征、肥胖、高胆固醇血症和高血压是有用的。